Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Early research (Phase 1)Study completedNCT01284192What this trial is testingStudy of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)Who this might be right forAdvanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROS+2 more Astellas Pharma Inc 46
Testing effectiveness (Phase 2)Study completedNCT01945021What this trial is testingPhase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCWho this might be right forNon Small Cell Lung CancerROS1 Proto OncogeneCrizotinib Pfizer 129
Testing effectiveness (Phase 2)UnknownNCT02927340What this trial is testingLorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsWho this might be right forNon-Small Cell Lung Cancer (NSCLC) Massachusetts General Hospital 30
Very early researchLooking for participantsNCT06333899What this trial is testingLorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionWho this might be right forHigh Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic Astrocytoma+6 more Nationwide Children's Hospital 15